ENGN
enGene Holdings Inc.
Biotechnology
Market Cap$83M
5Y Perf.-78.9%
Build Your Comparison
Side-by-side financial analysisENGN
JANX
IMVT
FATE
Try popular comparisons:
Stock Comparison
ENGN vs JANX vs IMVT vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
JANX
Janux Therapeutics, Inc.
Biotechnology
Market Cap$827M
5Y Perf.+55.3%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.-14.1%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$240M
5Y Perf.-17.3%
ENGN vs JANX vs IMVT vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ENGN |  JANX |  IMVT |  FATE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $83M | $827M | $6.90B | $240M |
| Revenue (TTM) | — | $22M | $0.00 | $6M |
| Net Income (TTM) | $-122M | $-114M | $-506M | $-130M |
| Gross Margin | — | 54.1% | — | 53.8% |
| Operating Margin | — | -7.3% | — | -22.1% |
| Total Debt | $32M | $22M | $72K | $78M |
| Cash & Equiv. | $50M | $52M | $902M | $47M |
ENGN vs JANX vs IMVT vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ENGN
JANX
IMVT
FATE
| Stock | Nov 23 | Jun 26 | Return |
|---|---|---|---|
| enGene Holdings Inc. (ENGN) | 100 | 21.1 | -78.9% |
| Janux Therapeutics,… (JANX) | 100 | 155.3 | +55.3% |
| Immunovant, Inc. (IMVT) | 100 | 85.9 | -14.1% |
| Fate Therapeutics, … (FATE) | 100 | 82.7 | -17.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ENGN vs JANX vs IMVT vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JANX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. enGene Holdings Inc. is the stronger pick specifically for profitability and margin quality. IMVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇JANX emerged as the overall leader. Track its performance:
ENGN
enGene Holdings Inc.
The Quality Compounder
ENGN is the #2 pick in this set and the best alternative if quality is your priority.
- 2.9% margin vs FATE's -20.6%
Best for: quality
JANX
Janux Therapeutics, Inc.
The Income Pick
JANX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.41
- Rev growth -5.6%, EPS growth -43.0%, 3Y rev CAGR 5.1%
- Lower volatility, beta 1.41, Low D/E 2.3%, current ratio 39.04x
- Beta 1.41, current ratio 39.04x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 237.9% 10Y total return vs JANX's -46.1%
- +110.9% vs ENGN's -50.2%
Best for: long-term compounding
FATE
Fate Therapeutics, Inc.
The Secondary Option
FATE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  JANX | -5.6% revenue growth vs ENGN's -77.3% |
| Quality / Margins |  ENGN | 2.9% margin vs FATE's -20.6% |
| Stability / Safety | JANX | Beta 1.41 vs ENGN's 2.26, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  IMVT | +110.9% vs ENGN's -50.2% |
| Efficiency (ROA) | JANX | -11.2% ROA vs IMVT's -62.2% |
ENGN vs JANX vs IMVT vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2023
ENGN vs JANX vs IMVT vs FATE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJANXLAGGINGFATE
Who Leads Where
JANX leads in 1 of 6 categories
IMVT leads 1 • ENGN leads 0 • FATE leads 0 • 3 tied
Explore the data ↓FATEFate Therapeutics, In…
0leads
ENGNenGene Holdings Inc.
0leads
IMVTImmunovant, Inc.
1leads
JANXJanux Therapeutics, I…
1leads
6 Total Categories
CATEGORYLEADERvs IMVTvs ENGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JANX4/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JANX leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JANX and IMVT operate at a comparable scale, with $22M and $0 in trailing revenue. JANX is the more profitable business, keeping -5.3% of every revenue dollar as net income compared to FATE's -20.6%.
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. |  FATEFate Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | — | $22M | $0 | $6M |
| EBITDAEarnings before interest/tax | -$127M | -$155M | -$532M | -$127M |
| Net IncomeAfter-tax profit | -$122M | -$114M | -$506M | -$130M |
| Free Cash FlowCash after capex | -$104M | -$78M | -$407M | -$108M |
| Gross MarginGross profit ÷ Revenue | — | +54.1% | — | +53.8% |
| Operating MarginEBIT ÷ Revenue | — | -7.3% | — | -22.1% |
| Net MarginNet income ÷ Revenue | — | -5.3% | — | -20.6% |
| FCF MarginFCF ÷ Revenue | — | -3.6% | — | -17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | -20.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +8.3% | -2.6% | -14.1% | +18.8% |
JANX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Evenly matched — ENGN and IMVT and FATE each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. | FATEFate Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $83M | $827M | $6.9B | $240M |
| Enterprise ValueMkt cap + debt − cash | $65M | $797M | $6.0B | $271M |
| Trailing P/EPrice ÷ TTM EPS | -0.71x | -7.41x | -12.14x | -1.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 82.69x | — | 36.13x |
| Price / BookPrice ÷ Book value/share | 0.49x | 0.88x | 7.19x | 1.18x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — ENGN and IMVT and FATE each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — JANX and IMVT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
JANX delivers a -11.8% return on equity — every $100 of shareholder capital generates $-12 in annual profit, vs $-68 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to FATE's 0.38x. On the Piotroski fundamental quality scale (0–9), IMVT scores 2/9 vs JANX's 1/9, reflecting mixed financial health.
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. | FATEFate Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -55.8% | -11.8% | -68.2% | -58.9% |
| ROA (TTM)Return on assets | -45.7% | -11.2% | -62.2% | -39.4% |
| ROICReturn on invested capital | -67.4% | -15.3% | — | -36.5% |
| ROCEReturn on capital employed | -50.7% | -15.6% | -68.3% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.19x | 0.02x | 0.00x | 0.38x |
| Net DebtTotal debt minus cash | -$18M | -$30M | -$902M | $31M |
| Cash & Equiv.Liquid assets | $50M | $52M | $902M | $47M |
| Total DebtShort + long-term debt | $32M | $22M | $72,000 | $78M |
| Interest CoverageEBIT ÷ Interest expense | -40.18x | — | — | — |
Evenly matched — JANX and IMVT each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $229 for FATE. Over the past 12 months, IMVT leads with a +110.9% total return vs ENGN's -50.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs ENGN's -56.7% — a key indicator of consistent wealth creation.
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. | FATEFate Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -81.7% | -0.7% | +29.8% | +108.1% |
| 1-Year ReturnPast 12 months | -50.2% | -46.9% | +110.9% | +47.1% |
| 3-Year ReturnCumulative with dividends | -91.9% | +4.4% | +55.0% | -61.9% |
| 5-Year ReturnCumulative with dividends | -91.9% | -32.7% | +213.0% | -97.7% |
| 10-Year ReturnCumulative with dividends | -91.9% | -46.1% | +237.9% | +15.7% |
| CAGR (3Y)Annualised 3-year return | -56.7% | +1.4% | +15.7% | -27.5% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — JANX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
JANX is the less volatile stock with a 1.41 beta — it tends to amplify market swings less than ENGN's 2.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 92.7% from its 52-week high vs ENGN's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. | FATEFate Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.26x | 1.41x | 1.66x | 1.93x |
| 52-Week HighHighest price in past year | $12.25 | $35.34 | $36.27 | $2.88 |
| 52-Week LowLowest price in past year | $1.40 | $12.12 | $14.32 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +38.4% | +92.7% | +71.5% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 44.4 | 57.9 | 47.8 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 884K | 1.9M | 3.2M |
Evenly matched — JANX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ENGN as "Hold", JANX as "Buy", IMVT as "Buy", FATE as "Buy". Consensus price targets imply 332.1% upside for ENGN (target: $7) vs 29.9% for IMVT (target: $44).
| Metric | ENGNenGene Holdings I… | JANXJanux Therapeutic… | IMVTImmunovant, Inc. | FATEFate Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $23.40 | $43.67 | $5.50 |
| # AnalystsCovering analysts | 9 | 15 | 23 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
JANX leads in 1 of 6 categories (Income & Cash Flow). IMVT leads in 1 (Total Returns). 3 tied.
Best OverallJanux Therapeutics, Inc. (JANX)Leads 1 of 6 categories
Loading custom metrics...
ENGN vs JANX vs IMVT vs FATE: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ENGN or JANX or IMVT or FATE a better buy right now?
For growth investors, Janux Therapeutics, Inc.
(JANX) is the stronger pick with -5. 6% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Janux Therapeutics, Inc. (JANX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ENGN or JANX or IMVT or FATE?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -97. 7% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus ENGN's -91. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ENGN or JANX or IMVT or FATE?
By beta (market sensitivity over 5 years), Janux Therapeutics, Inc.
(JANX) is the lower-risk stock at 1. 41β versus enGene Holdings Inc. 's 2. 26β — meaning ENGN is approximately 60% more volatile than JANX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ENGN or JANX or IMVT or FATE?
By revenue growth (latest reported year), Janux Therapeutics, Inc.
(JANX) is pulling ahead at -5. 6% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc. grew EPS 29. 9% year-over-year, compared to -56. 8% for enGene Holdings Inc.. Over a 3-year CAGR, JANX leads at 5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ENGN or JANX or IMVT or FATE?
enGene Holdings Inc.
(ENGN) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENGN leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — JANX leads at 79. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ENGN or JANX or IMVT or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ENGN or JANX or IMVT or FATE better for a retirement portfolio?
For long-horizon retirement investors, Janux Therapeutics, Inc.
(JANX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. enGene Holdings Inc. (ENGN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JANX: -46. 1%, ENGN: -91. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ENGN and JANX and IMVT and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.